PLC ε (C-18): sc-28404



The Boures to Overtion

BACKGROUND

Phosphoinositide-specific phospholipase C (PLC) plays a crucial role in the initiation of receptor mediated signal transduction through the generation of the two second messengers, inositol 1,4,5-triphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. There are many mammalian PLC isozymes, including PLC $\beta1$, PLC $\beta2$, PLC $\beta3$, PLC $\beta4$, PLC $\gamma1$, PLC $\gamma2$, PLC $\delta1$, PLC $\delta2$ and PLC ϵ). Phospholipase C ϵ (PLC ϵ) is characterized by possession of CDC25homology and Ras/Rap1-associating domains. PLC ϵ is translocated from the cytoplasm to the plasma membrane and activated by direct association with Ras at its Ras/Rap1-associating domain.

REFERENCES

- Rhee, S.G., et al. 1992. Regulation of inositol phospholipid-specific phospholipase C isozymes. J. Biol. Chem. 267: 12393-12396.
- Kelley, G.G., et al. 2001. Phospholipase Cε: a novel Ras effector. EMBO J. 20: 743-754.
- 3. Jin, T.G., et al. 2001. Role of the CDC25 homology domain of phospholipase $C\epsilon$ in amplification of Rap1-dependent signaling. J. Biol. Chem. 276: 30301-30307.
- 4. Wing, M.R., et al. 2001. Activation of phospholipase C- ϵ by heterotrimeric G protein $\beta\gamma$ -subunits. J. Biol. Chem. 276: 48257-48261.
- 5. Song, C., et al. 2002. Differential roles of Ras and Rap1 in growth factor-dependent activation of phospholipase $C\epsilon$. Oncogene 21: 8105-8113.
- 6. Wu, D., et al. 2003. Neuronal lineage-specific induction of phospholipase $C\epsilon$ expression in the developing mouse brain. Eur. J. Neurosci. 17: 1571-1580.
- 7. Wing, M.R., et al. 2003. Direct activation of phospholipase C- ϵ by Rho. J. Biol. Chem. 278: 41253-41258.
- 8. Wing, M.R., et al. 2003. PLC- ϵ : a shared effector protein in Ras-, Rho-, and $G_{\alpha\beta\gamma}$ -mediated signaling. Mol. Interv. 3: 273-280.

CHROMOSOMAL LOCATION

Genetic locus: PLCE1 (human) mapping to 10q23.33; Plce1 (mouse) mapping to 19 C3.

SOURCE

PLC ϵ (C-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of PLC ϵ of mouse origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-28404 P, (100 μg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

PLC ϵ (C-18) is recommended for detection of PLC ϵ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

PLC ϵ (C-18) is also recommended for detection of PLC ϵ in additional species, including equine, canine, bovine and avian.

Suitable for use as control antibody for PLC ϵ siRNA (h): sc-44024, PLC ϵ siRNA (m): sc-152295, PLC ϵ shRNA Plasmid (h): sc-44024-SH, PLC ϵ shRNA Plasmid (m): sc-152295-SH, PLC ϵ shRNA (h) Lentiviral Particles: sc-44024-V and PLC ϵ shRNA (m) Lentiviral Particles: sc-152295-V.

Molecular Weight of PLC ε: 255 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

SELECT PRODUCT CITATIONS

1. Heeringa, S.F., et al. 2011. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J. Clin. Invest. 121: 2013-2024.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com